

# Geographic distribution of anti-Leptospira antibodies in humans in Côte d'Ivoire, West Africa

Stephane Kouadio Koffi, Syndou Meite, Abdoulaye Ouattara, Stephane Kan Kouassi, Sylla Aboubacar, Veronique Agbaya Akran, Pascale Bourhy, Mireille

Dosso

### ► To cite this version:

Stephane Kouadio Koffi, Syndou Meite, Abdoulaye Ouattara, Stephane Kan Kouassi, Sylla Aboubacar, et al.. Geographic distribution of anti-Leptospira antibodies in humans in Côte d'Ivoire, West Africa. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37 (11), pp.2177-2180. 10.1007/s10096-018-3359-7. pasteur-03251358

### HAL Id: pasteur-03251358 https://pasteur.hal.science/pasteur-03251358

Submitted on 7 Jun2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

- 1 Geographic distribution of anti-Leptospira antibodies in humans in Côte
- 2 d'Ivoire, West Africa.
- 3
- Koffi Kouadio Stephane<sup>1,2</sup>, Meite Syndou<sup>1</sup>, Ouattara Abdoulaye<sup>1</sup>, Kouassi Kan Stephane<sup>1</sup>, Sylla
  Aboubacar<sup>1</sup>, Akran Agbaya Veronique<sup>1</sup>, Bourhy Pascale<sup>3</sup>, Dosso Mireille<sup>1</sup>.
- 6 1 : Institut Pasteur de Côte d'Ivoire
- 7 2 : UFR Sciences médicales Université F. Houphouët-Boigny/CHU de Cocody
- 8 3 : Centre National de Référence de la leptospirose, Institut Pasteur de Paris
- 9
- 10 Corresponding author
- 11 KOFFI Kouadio Stéphane
- **12** 08 BP 919 Abidjan 08
- **13** Tel: (225) 05788663
- 14 Koffi.ks@gmail.com

#### 15 INTRODUCTION

- 16 Leptospirosis is a zoonotic bacterial disease with a worldwide distribution caused by pathogenic
- 17 bacteria of the genus *Leptospira* [1]. It is an endemic disease especially in subtropical and tropical
- 18 regions and outbreaks can occur after heavy rain or flooding [1]. Transmission occurs through direct or
- indirect contact with urine of infected animals [1, 2].
- Leptospirosis may be unrecognized or misdiagnosed because of the lack of specific clinical symptoms,
   thus human incidence is commonly underreported.
- The World Health Organization (WHO) Leptospirosis Epidemiology Reference Group (LERG)estimated the leptospirosis incidence at 1.03 million cases and 58,900 deaths each year worldwide [3].
- 24 West African annual leptospirosis incidence was estimated to be 9.7 per 100,000 population [3].
- 25 In West Africa, few studies on *Leptospira* prevalence have been published. And prevalence of acute
- human leptospirosis ranged from 0.0% to 7.8% in five studies on symptomatic patients [4, 5].
- In Côte d'Ivoire, data are sparse, however an unpublished study carried out in 2013 by the "Centre
  Suisse de Recherche Scientifique" in Yopougon (Abidjan) showed, 4% prevalence in both 124 febrile
- 29 patients and 99 rodents using MAT showing human and animal infection. Another study showed high
- prevalence in 93 vaccinated dogs (58%) and 63 non-vaccinated dogs (47%) sampled in Abidjan and in two neighbouring cities using MAT suggesting human exposure [6].
- 31 two neighbouring cities using MAT suggesting numan exposure [6].
   32 Thus, little is known about leptospirosis in the country and data are needed
- 32 Thus, little is known about leptospirosis in the country and data are needed to inform burden estimates 33 and to inform intervention strategies. Mapping leptospirosis exposure could help find high-risk areas 34 and lead intervention choices against the disease. This study aims to determine the geographic 35 distribution of anti-*Leptospira* antibodies in humans in Côte d'Ivoire.
- 36

#### 37 MATERIAL AND METHODS

- 38 This study was carried out from August to November 2015 in the 82 health districts of Côte d'Ivoire.
- The study was carry out on stored human specimens previously collected for the national surveillancesystem for communicable diseases in 2014. Only negative specimens were included in the study.
- 41 One to 13 serum samples were randomly selected per health district based on the number of notified 42 cases by health districts in the year to obtain a sample size of 384.
- Blood samples were collected from each patient who matches the clinical WHO's case definition for notifiable disease. Samples were sent, at +4°C, to the National Reference Centre at the Institut Pasteur
- 44 notifiable disease. Samples were sent, at +4 C, to the National Reference Centre at the Institut Pasteur 45 de Côte d'Ivoire for analysis. Anti-*Leptospira* antibody testing was carried out at Institut Pasteur de
- 46 Côte d'Ivoire (IPCI) and Institut Pasteur in Paris (IP). We used as screening methods the ELISA
- 47 against type IgG anti-*Leptospira* antibodies previously describe by Bourhy et al. (2013) in IPCI [7].
  48 Confirmation was carried out by MAT in IP with a threshold of 1:50. As antigens, 16 serogroups were
- 48 Confirmation was carried out by MAT in IP with a threshold of 1:50. As antigens, 16 serogroups were49 used (table 1).
- 50 Socio-demographic and clinical data from the National Reference Centre, which manage the samples
- 51 and results for analysis performed on studied samples, were used to build a database using Epi Info
- 52 software (CDC, Atlanta, Georgia). Data analyses were done using R software 3.2.0 [8].
- 5354 RESULTS
- Age of patients ranged from 1 month to 78 years old with a mean age of 20.8 years. Patients less than
  25 years were more represented with 60.9% of all patients. We noted a male predominance with a sex
  ratio of 1.55.
- 58 Of the samples tested, ELISA positively screened 90. Of these, 36 were confirmed by MAT 59 representing 9.4 % prevalence. People with anti-*Leptospira* antibodies had a mean age of 34.5 years 60 and a Sex ratio of 2. Of the 82 health districts of the country, anti-*Leptospira* antibodies were found in 61 samples from 22. Health districts with anti-*Leptospira* antibodies were mostly located in the western
- samples from 22. Health districts with anti-*Leptospira* at and the southern parts of the country (fig 1).
- 63 MAT anti-*Leptospira* antibodies titre ranged from 1:50 to 1:6400. Eight different serogroups of 64 *Leptospira* were found (table 2). Serogroup Panama was the most frequent (36.1 %) followed by
- 65 Louisiana (19.4 %) and Grippotyphosa and Sejroe (11.1% respectively).
- 66

#### 67 **DISCUSSION**

68 This study focuses on anti-*Leptospira* antibodies in human specimens collected in the national 69 surveillance system for communicable diseases in Côte d'Ivoire. Few published data on *Leptospira* and 70 leptospirosis in Côte d'Ivoire are available [4, 5, 9]. Our study, which focus on type IgG antibodies 71 showed a prevalence of 9.4%. This result is in accordance with the LERG who estimated an annual 72 incidence for leptospirosis to 9.6% in the West sub-Saharan Africa WHO region [3].

73 Samples from all the 82 health districts of the country were included in this study. So, the studied 74 population were representative of all the country. However, health districts with anti-Leptospira 75 antibodies found in this study were mostly located in the western and the southern parts of the country 76 (fig 1). These parts of the country are peculiar by their climate and forest cover. They are the most 77 humid parts of the country with higher forest cover and heavy raining season compare to the northern 78 part of the country, which is mostly arid. It's actually well known that leptospirosis is related to water 79 and wet soils were *Leptospira* find proper conditions for his maintenance in the environment [10, 11, 80 12]. In these parts of the country, some irrigated farming activities like rice, banana and vegetable 81 farming are associated with risk behaviours like walking barefooted in wet farm soil, sludge or working 82 without wearing appropriated personal protective equipment. The maintenance of Leptospira in the 83 environment is better when bacteria are protected from direct UV sunlight [13]. This situation could be 84 achieved in forests or in large farms with trees like cocoa, coffee or rubber plantations mostly seen in 85 the western and southern part of the country. These plantations also offer habitats to small mammals 86 that are considered a reservoir of bacteria and create a Human/ Animal/ Environment interface, which 87 could improve the transmission of the disease.

Regarding people with anti-*Leptospira* antibodies, they were young adults (mean age 34.5 years)
mostly men (sex ratio 2) living in rural area; corresponding to active low-income farmers working into
agricultural fields. These people could represent an at-risk population and it could be suitable to
implement prevention activities against leptospirosis related to them. Indeed, farming is a major
activity in Côte d'Ivoire representing 43.5 % of jobs.

93 This study highlights the circulation of leptospirosis among people in Côte d'Ivoire. Unfortunately, no 94 routine laboratory-based diagnostic strategies are available for leptospirosis or other diseases such as 95 rickettsia or viral hepatitis. Numerous patients suffering from infectious diseases are not correctly 96 diagnosed, and the burden of these diseases is underestimated. Early diagnosis and treatment reduce 97 occurrence of complications and improve recovery rate significantly [1]. There is a need to improve 98 public health by Ivorian authorities and their international partners.

99

#### 100 COMPLIANCE WITH ETHICAL STANDARDS

101 Funding: No funding was received.

- 102 **Conflict of Interest**: The authors declare that they have no conflict of interest.
- 103 Ethical approval: The national ethic and research committee of Côte d'Ivoire approved this study
- 104 under the number 23/MSLS/CNER-dkn.
- **105 Informed consent**: Not applicable.

## 106

#### 107 **REFERENCES**

- Haake DA, Levett PN (2015) Leptospirosis in humans. Curr Top Microbiol Immunol 387:65-97.
   doi: 10.1007/978-3-662-45059-8\_5.
- Hartskeerl RA, Collares-Pereira M, Ellis WA (2011) Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world. Clinical Microbiology and Infection 17:494–501. doi: 10.1111/j.1469-0691.2011.03474.x.
- Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, Stein C, Abela-Ridder B, Ko AI. (2015) Global Morbidity and Mortality of Leptospirosis: A Systematic Review.
   PLoS Negl Trop Dis 9: e0003898. doi: 10.1371/journal.pntd.0003898.
- De Vries SG, Visser BJ, Nagel IM, Goris MG, Hartskeerl RA, Grobusch MP (2014) Leptospirosis in Sub-Saharan Africa: a systematic review. Int J Infect Dis 28:47-64.

- 118 5. Allan KJ, Biggs HM, Halliday JEB, Kazwala RR, Maro VP, Cleaveland S, Crump JA. (2015)
  119 Epidemiology of Leptospirosis in Africa: A Systematic Review of a Neglected Zoonosis and a
  120 Paradigm for 'One Health' in Africa. Plos Neglected Tropical Diseases 9: 3899–3899.
- 121 6. Roqueplo C, Marié JL, André-Fontaine G, Kodjo A, Davoust B (2015) Serological survey of canine leptospirosis in three countries of tropical Africa: Sudan, Gabon and Ivory Coast. Comp
  123 Immunol Microbiol Infect Dis 38:57-61. doi: 10.1016/j.cimid.2014.10.006.
- Bourhy P, Vray M, Picardeau M (2013) Evaluation of an in-house ELISA using the intermediate
   species *Leptospira fainei* for diagnosis of leptospirosis. J Med Microbiol 62(Pt 6):822-7.
- 126 8. R Core Team (2015) R: A language and environment for statistical computing. R Foundation for
   127 Statistical Computing, Vienna, Austria. URL http://www.R-project.org
- Pappas G, Papadimitriou P, Siozopoulou V, Christou L, Akritidis N (2008) The globalization of
   leptospirosis: worldwide incidence trends. Int J Infect Dis 12(4):351-7. Epub 2007 Dec 4.
- 130 10. Adler B, De La Pena Moctezuma A (2010) *Leptospira* and leptospirosis. Veterinary Microbiology
   131 140: 287–296. doi: 10.1016/j.vetmic.2009.03.012.
- 132 11. Faine S, Adler B, Bolin C, Pérolat P (1999) *Leptospira* and leptospirosis. Melbourne, Australia:
   133 MediSci. 296 p.
- 134 12. Levett PN (2001) Leptospirosis. Clinical Microbiology Reviews 14(2):296–326.
- 135 13. Stamm LV, Charon NW (1988) Sensitivity of pathogenic and free-living *Leptospira spp.* to UV
   radiation and mitomycin C. Appl Environ Microbiol 54(3): 728–733.
- 137

#### 138 FIGURE CAPTIONS

- 139 Fig 1 shows health districts were people with anti-*Leptospira* antibodies were found. Colors are related
- to number of cases found